The US Food and Drug Administration (FDA) has approved  Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 to treat metastatic castration-resistant prostate cancer (mCRPC).

An investigational orally bioavailable, chimeric degrader molecule, AC0176 is designed to target and degrade androgen receptor (AR) to treat prostate cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AR is a hormone-regulated transcription factor that plays a key role in initiation and progression of prostate cancer.

Accutar stated that AC0176 showed strong and selective degradation of AR protein with wide coverage of AR mutants and favourable pharmacological properties in the preclinical studies.

In the Phase 1 study, AC0176’s pharmacokinetics, preliminary anti-tumour activity, safety, and tolerability will be evaluated to treat mCRPC patients.

Accutar Biotechnology CEO Jie Fan said: “The IND clearance for AC0176 is another important validation, after our AC0682 entered the clinic recently, that our AI platform can support and advance the discovery of potentially differentiated clinical candidates quickly, especially complex compounds such as chimeric degraders.

“The IND clearance for AC0176 is also critical towards offering a potential new treatment for prostate cancer based on a differentiated mechanism of action from second generation nonsteroidal AR antagonists, which are the current standard of care for this patient population.

“We look forward to the clinical benefit that AC0176 treatment can potentially provide to prostate cancer patients.”

The company expects to commence enrolment of participants for the Phase I clinical trial in the first quarter of next year.

Recently, CytoDyn received positive response from the US FDA to commence a Phase III clinical trial of leronlimab to treat Covid-19.